Galapagos NV (NASDAQ:GLPG - Get Free Report) has earned an average recommendation of "Reduce" from the eight ratings firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $30.75.
GLPG has been the subject of a number of recent research reports. Kepler Capital Markets lowered shares of Galapagos from a "hold" rating to a "reduce" rating in a research note on Wednesday, November 20th. Royal Bank of Canada reduced their target price on shares of Galapagos from $32.00 to $30.00 and set a "sector perform" rating for the company in a research report on Friday, November 1st. Finally, TD Cowen cut Galapagos from a "strong-buy" rating to a "strong sell" rating in a research report on Thursday.
View Our Latest Stock Report on Galapagos
Galapagos Trading Down 5.5 %
Shares of Galapagos stock traded down $1.41 during midday trading on Monday, hitting $24.24. 410,835 shares of the company traded hands, compared to its average volume of 305,734. The firm's fifty day moving average price is $27.23 and its 200-day moving average price is $27.53. Galapagos has a 12 month low of $24.10 and a 12 month high of $40.34.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning purchased a new stake in shares of Galapagos during the second quarter valued at $456,000. GAMMA Investing LLC boosted its stake in Galapagos by 77.4% in the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after acquiring an additional 974 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new position in Galapagos during the 3rd quarter valued at about $1,077,000. Signaturefd LLC boosted its stake in Galapagos by 65.6% in the 3rd quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company's stock worth $185,000 after purchasing an additional 2,541 shares in the last quarter. Finally, Headlands Technologies LLC increased its holdings in shares of Galapagos by 56.7% in the second quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 446 shares during the period. Hedge funds and other institutional investors own 32.46% of the company's stock.
About Galapagos
(
Get Free ReportGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Featured Articles
Before you consider Galapagos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.
While Galapagos currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
